×
Tracking SARS-CoV-2 variants
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
World Health Organization

May 31st, 2021 - All viruses, including SARS-CoV-2, the virus that causes COVID-19, change over time. Most changes have little to no impact on the virus’ properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures.

ESMO Virtual Congress 2020: Meeting
https://www.esmo.org/meetings/esmo-virtual-congress-2020

Sep 18th, 2020 - Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track. Take part in Europe's most prestigious platform for oncology stakeholders.

RECOVER Researchers Express Hope and Frustration in Their Study of Long COVID
https://www.medpagetoday.com/special-reports/exclusives/99403
MedPage Today; DePeau-Wilson M.

Jul 23rd, 2022 - Slow enrollment has led to simmering frustrations over the progress and potential of the NIH's RECOVER Initiative, the research consortium focused on studying post-acute sequelae of SARS-CoV-2, or long COVID, according to researchers and leaders within the initiative. The RECOVER Initiative was designed to support research on long COVID across the U.S., including among every group of people ...

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768602
JAMA Internal Medicine;

Jul 15th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...

COVID-19 in Immunocompromised Hosts: What We Know So Far
https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa863/5864040
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.

Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...

Progressing malignancy linked to higher mortality among patients with cancer and COVID-19
https://www.healio.com/hematology-oncology/practice-management/news/online/{a24c9adf-558c-4ccb-ba95-8c5a2168dcbe}/progressing-malignancy-linked-to-higher-mortality-among-patients-with-cancer-and-covid-19

May 31st, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair
https://ascopost.com/videos/asco20-virtual-scientific-program/merry-jennifer-markham-perspectives-on-three-abstracts/

May 30th, 2020 - Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.

Widespread Impact of COVID-19 on Cancer Research and Treatment
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200211/full/

May 30th, 2020 - There is no doubt that the COVID-19 pandemic has negatively affected cancer research and patient treatment worldwide. ASCO addressed this during the ASCO20 Virtual Scientific Program during the session, “Cancer Care in the Time of COVID: Assessing Impact and Future Directions.” The session began with an overview given by Norman E. Sharpless, MD, director of the National Cancer Institute (NCI). ...

NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research
https://www.healio.com/hematology-oncology/practice-management/news/online/{56279316-24e1-4c34-8527-2538a95b52a9}/nci-director-covid-19-having-profound-effects-on-cancer-outcomes-research

May 30th, 2020 - The oncology community has demonstrated a remarkable ability to adapt amid the COVID-19 pandemic but must be prepared for its long-term effects on cancer care, NCI Director Norman E. “Ned” Sharpless, MD, told ASCO Virtual Scientific Program attendees.

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 29th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

Prior chemotherapy linked to mortality risk among patients with thoracic cancers, COVID-19
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{57d3d009-7215-423e-a152-9ff210a6afaa}/prior-chemotherapy-linked-to-mortality-risk-among-patients-with-thoracic-cancers-covid-19

May 29th, 2020 - Prior use of chemotherapy appeared associated with an increased risk for death among patients with lung or other thoracic cancers and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Patients With Cancer—Especially Progressive Disease—Infected With COVID-19 May Have an Increased Risk of Death
https://ascopost.com/news/may-2020/patients-with-cancer-especially-progressive-disease-infected-with-covid-19-may-have-an-increased-risk-of-death/

May 29th, 2020 - A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe illness were associated with general risk factors, as well as those unique to patients with cancer, a...

Active Cancer Strongly Associated With Increased COVID-19 Mortality
https://www.onclive.com/conference-coverage/asco-2020/active-cancer-strongly-associated-with-increased-covid19-mortality

May 28th, 2020 - An analysis of data collected in the COVID-19 and Cancer Consortium (CCC19) registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 (COVID-19) compared with patients in remission or with no evidence of disease.

Recent Chemotherapy Raises COVID-19-Related Mortality Risk for Patients With Thoracic Cancer
https://www.onclive.com/conference-coverage/asco-2020/recent-chemotherapy-raises-covid19related-mortality-risk-for-patients-with-thoracic-cancer

May 28th, 2020 - Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.

Study Opens Up Possibility for Use of Precision Medicine in Pediatric Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86732

May 28th, 2020 - Matching children diagnosed with advanced cancers to targeted anti-cancer agents appears to show some potential for improving progression-free survival, researchers reported in a late-breaker abstract at the virtual American Society of Clinical Oncology (ASCO) annual meeting, with presentations online this year due to the COVID-19 pandemic.

COVID-19 in Thoracic Cancer Patients a Killer
https://www.medpagetoday.com/meetingcoverage/asco/86736

May 28th, 2020 - share to facebook share to twitter share to linkedin email article COVID-19 and cancers of the chest cavity make a deadly combination, researchers reported at the virtual meeting of the the American Society of Clinical Oncology (ASCO).

HCQ Linked to Harm in Cancer Patients
https://www.medpagetoday.com/meetingcoverage/asco/86738

May 28th, 2020 - Use of hydroxychloroquine in cancer patients who are also diagnosed with COVID-19 provided no benefits, and may have worsened outcomes, researchers suggested.

COVID-19-Related Mortality Risk Increases With Recent Chemotherapy in Thoracic Cancer
https://www.targetedonc.com/view/covid-19-related-mortality-risk-increases-with-recent-chemotherapy-in-thoracic-cancer

May 28th, 2020 - The risk of death in patients with thoracic cancer was inflated with the administration of chemotherapy within 3 months of a coronavirus disease 2019 (COVID-19) diagnosis, findings from the global TERAVOLT Consortium registry show.

COVID-19 Mortality Shows Strong Correlation With Active Cancer
https://www.targetedonc.com/view/covid-19-mortality-shows-strong-correlation-with-active-cancer

May 28th, 2020 - Death in patients with progressive cancer within 30 days of the coronavirus disease 2019 (COVID-19) diagnosis was 5.2 times compared with patients in remission or with no evidence of disease, data from the COVID-19 and Cancer Consortium (CCC19) registry shows.

The hallmarks of COVID-19 disease
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008536
PLoS Pathogens;

May 22nd, 2020 - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that has caused a worldwide pandemic of the human respiratory illness COVID-19, resulting in a severe threat to public health and safety.